Skip to content

PTC Therapeutics PTCT US — PP&E (Net)

Similar metrics at other companies

Pool Corporation logo
POOLUS — PP&E (Net)
$256.9M+6.2%
Glaukos logo
GKOSUS — PP&E (Net)
$112.16M+16.1%
NOVA, Inc. logo
NOVUS — PP&E (Net)
$941M+1.4%
LEC
LECOUS — PP&E (Net)
$403.12M+17.0%
ESCO Technologies logo
ESEUS — PP&E (Net)
$142.34M+8.7%
Armstrong World Industries logo
AWIUS — PP&E (Net)
$624.7M+5.1%

Other financials

Income statement

See full
Revenue$272.6M-76.8%
Operating income$45.0M-95.4%
Net income-$2.8M-100%
EPS (diluted)-$0.03-100%

Balance sheet

See full
Cash & equivalents$834.0M-43.7%
Total debt$395.1M+0.1%
Total equity-$180.5M+2.9%
Total assets$2.9B+8.0%

Cash flow

See full
Operating cash flow-$59.0M-107%
CapEx$1.2M-30.6%
Free cash flow-$60.2M-107%

Valuation

See full
Market cap$6.55B+40.3%
Enterprise value$6.11B+77.3%
P/E
P/S7.9×+5.3×

Profitability

See full
Gross margin96%
Operating margin1.6%-38.7pp
Net margin42.3%+27.4pp
FCF margin39.1%+32.8pp

Returns & leverage

See full
Return on equity-216.7%
Debt / equity372.3×
Current ratio2.4×-1.5×

Where this comes from

Reported directly by PTC Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: PTC Therapeutics’s 10-K, filed February 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTC Therapeutics's us — pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is PTC Therapeutics's US — PP&E (net)?
PTC Therapeutics (PTCT) reported US — PP&E (net) of $54.11M in Q4 2025.
How has PTC Therapeutics's US — PP&E (net) changed year-over-year?
PTC Therapeutics's US — PP&E (net) decreased by 9.4% year-over-year, from $59.75M to $54.11M.
What does US — PP&E (net) mean?
This metric measures the net book value of the company's physical infrastructure, such as laboratories, manufacturing facilities, and office equipment, situated in the United States. It reflects the company's investment in the physical capacity required to support its research, development, and commercialization activities. Changes in this metric indicate the company's commitment to expanding or maintaining its domestic operational footprint.